Glaukos's ROE % for the quarter that ended in Mar. 2026 was -11.93%. Glaukos's PB Ratio for the quarter that ended in Mar. 2026 was 9.36.
Glaukos's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -1.27%.
Glaukos ROE % Adjusted to Book Value Related Terms
Glaukos ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Glaukos's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKOS vs LIVN, BIO, IRTC: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Glaukos's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Glaukos's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -1.27% mean?
Glaukos (GKOS) has a ROE % Adjusted to Book Value of -1.27% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Glaukos and its competitors.
Is Glaukos' ROE % Adjusted to Book Value too high?
Glaukos' current ROE % Adjusted to Book Value is -1.27%. Overall, Glaukos has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' ROE % Adjusted to Book Value compare to LIVN and BIO?
Glaukos' ROE % Adjusted to Book Value of -1.27% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Glaukos and its competitors. Glaukos's current ROE % Adjusted to Book Value is -1.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Fairly Valued. The stock's GF Value™ is $135.34, compared to a current price of $137.76 — trading 1.8% above its estimated fair value. The current ROE % Adjusted to Book Value is -1.27%. Glaukos' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Glaukos (GKOS), the current ROE % Adjusted to Book Value is -1.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $137.76 is trading 1.8% above its estimated GF Value™ of $135.34.
GuruFocus considers Glaukos to be Fairly Valued.
Key valuation signals for GKOS:
ROE % Adjusted to Book Value: -1.27%
GF Value™: $135.34 vs. price of $137.76 (1.8% above fair value)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
81GF Score
Get the complete analysis for GKOS
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
